Your address will show here +12 34 56 78
  • Text Hover
AVEX Impact
Enabling the Real World Impact of Health Innovation
AVEX Impact is the nonprofit arm of AEVOLVE AG, a project designed to accelerate the pace of innovation in the health space. AVEX Impact was designed to nurture a spirit of community, participation, and purpose—to further the objectives and reach of AEVOLVE AG’s supported technologies.

As the COVID-19 pandemic continues to deepen its effect on the world’s health and economic climate, the AVEX Impact as a nonprofit organization is playing a major role in ensuring that the innovations in health technology are within reach of those who need it most, instituting programs of relevance that benefit both promising COVID-19 medical solutions and patients.

Our launch project is a strategic program with American Dream Present, Sterling Promotions and J3G Global. We are jointly developing a new platform that merges premium entertainment and world-class boxing events managed by industry icons with the novel financing models made possible by AEVOLVE.

Our Impact Goal in 2020 is to create new opportunities that expand support for health solutions and medical research initiatives through nonprofit and philanthropic efforts.
  • Text Hover
We have initiated support for NuCISION, Inc a biotech
Company working on a novel therapeutic for COVID-19.
NuCISION’s technology proposes a new antiviral model that opens up a new approach towards beating the virus. It is developing a novel cell-penetrating programmable enzyme-based anti-viral model to directly address SARS-CoV-2. 

This new medical technology, which is a departure from antibody or vaccine approaches, is expected to enter human trials by Q4 2021.
  • Text Hover
  • Text Hover

Select country

Select language

Important Information

The information on this website is intended only for persons residing or having their registered office in Switzerland.

By using this website, you expressly confirm that you are a resident of the selected country. Aevolve AG explicitly declines any responsibility for the distribution of information or documents to natural or legal persons who provide incorrect information regarding their legal place of residence or registered office.

The financial products mentioned on this website are derivative financial instruments. They do not qualify as units of a collective investment scheme in the meaning of Article 7 et seqq. of the Swiss Federal Act on Collective Investment Schemes (CISA) and are therefore neither supervised by the Swiss Financial Market Supervisory Authority (FINMA) nor registered with FINMA. Investors do not benefit from the specific investor protection provided under the CISA.

Terms of use and legal information 


By using the Aevolve AG website (hereinafter “Website”), you confirm that you have understood and accept the legal information, important notes and terms of use presented here. If you do not accept the terms of use, please refrain from using this Website.

Proprietary information


All intellectual property rights (e.g. copyright, design and trademark rights) to the material presented on the Website belong to Aevolve AG or its platform partners, who will enforce these rights to the full extent of applicable laws. Any form of reproduction, republication or distribution of the content of this Website requires the written consent of Aevolve AG in Zurich (Switzerland) and the respective indication of the source.

No part of this Website is designed to grant any form of license or user rights to images, text, trademarks or logos. No act of downloading or copying content from the Website will transfer or bestow any legal entitlement to the Website’s software or materials.

Conflicts of interest


From time to time, the issuers and/or lead manager and/or their third-party agents may, for their own account or for the account of others, take positions in securities, currencies, financial instruments or other assets that serve as an underlying asset to the products on this Website. They may buy or sell these assets, act as market makers, and simultaneously operate as seller or as purchaser. The trading or hedging activities of the issuers and/or lead manager and/or their third-party agents may influence the price of an underlying asset and may influence whether or not the relevant barrier level is reached (if such a level exists).



Past performance is not an indication or guarantee of future performance of a product or underlying asset. The value of any investment may be subject to fluctuations and, in some circumstances, investors may not recover the original amount invested. Exchange rate fluctuations may also cause the value of an investment to rise or fall.

Selling restrictions


No action has been or will be taken to permit a public offering of the products or possession or distribution of any offering material in relation to the products in any jurisdiction, where such action for that purpose is required. Selling Restrictions Consequently, any offer, sale or delivery of the products, or distribution or publication of any offering material relating to the products, may only be made in or from any jurisdiction in compliance with applicable laws and regulations not imposing any obligations on the issuers or the lead manager. Possible limitations resulting from legal restrictions with regard to cross-border communication and cross-border business concerning the products and related information remain reserved. The most important jurisdictions where the products may not be publicly distributed are EEA, UK, Hong Kong and Singapore.

The products may not be offered or sold within the USA, or to or for the account or benefit of US persons (as defined in Regulation S).

Detailed information on selling restrictions is published in the respective issuance programme, which is published on this Website and at